Summary and conclusions Twenty-seven children with perennial rhinitis entered a double-blind cross-over study comparing nasal sprays of flunisolide-a new topical corticosteroid-and placebo. Symptoms were assessed over two consecutive monthly periods with each treatment. Weekly diary cards, monthly clinical assessments, and end-of-trial preferences all favoured the active drug. At the end of the trial 20 patients preferred the treatment month with flunisolide, four preferred the placebo month, and two rated the periods equally. Side effects were mild, the commonest being transient nasal stinging.
Introduction
Perennial rhinitis is common in childhood and impairs the quality of life. Complications include speech problems and hearing loss, and many patients suffer unwanted effects of symptomatic drug treatment. The condition has an allergic aetiology in most cases, but avoidance regimens are seldom successful. Topical treatment with beclomethasone dipropionate may be used safely for prophylaxis against seasonal and perennial rhinitis in children,12 though some fail to derive benefit. wlunisolide, a new steroid with good topical activity, is safe and effective in adults3-6 and may be of value in children.7 8 We have therefore assessed the efficacy of flunisolide nasal spray in a group of children with perennial rhinitis.
Patients and methods
Twenty-seven children with clinical evidence of perennial allergic rhinitis entered the study. Twenty-one were boys and six girls, and their ages ranged from 7 to 16 years (mean age 12 3 years). The mean duration of disease was 7 4 years. All had been tested by skin-prick with various common allergens and shown a positive reaction to at least one, the most common response being to the house-dust mite. Eighteen children (67 o) had a family history of allergic disease, and 19 (700,) had one or more other allergic problems, usually asthma.
None of the children was taking oral corticosteroids or using any local nasal treatment at the start of the trial. Drugs regularly used for other concurrent illnesses were sodium cromoglycate inhalations (1 patient), beclomethasone dipropionate pulmonary aerosol (4), and corticosteroid creams (3). Seventeen had used a beclomethasone dipropionate nasal spray, but only five had obtained a "good" response.
The active agent contained flunisolide as an aqueous propylene glycol solution (0O025O0 w/v) and was supplied in glass bottles fitted with a mechanical pump spray delivering 01 ml per actuation. The placebo consisted of the vehicle alone in identical bottles. The study had a double-blind, cross-over design. On admission the children were allocated at random to one of two groups. One received the active nasal spray for four weeks followed by four weeks with the placebo spray, and the other the same treatment but reversed. They were instructed to use one spray up each nostril three times daily at about eight-hour intervals. For patients using the active spray this provided a total daily dose of 150 [±g.
After the double-blind trial children who had obtained benefit from flunisolide were invited to continue using the spray for six months, an open assessment of any symptoms and side effects being made at two-month intervals. The older children had blood cortisol concentrations measured in samples taken at 0900. All children could reduce the frequency of sprays from three times to twice or once daily provided satisfactory control was maintained.
CLINICAL ASSESSMENT
Changes in the severity of disease activity were monitored by diary cards, monthly clinical assessments, and end-of-trial preferences.
Diary cards-At the end of each week the children or their parents recorded in a dairy card the severity of sneezing, stuffy nose, runny nose, and nose-blowing. Symptoms were graded none (0), mild (1), moderate (2), or severe (3).
Monthly clinical assessments-Patients were assessed in the clinic on admission to the study and at the end of each drug-treatment period. The severity of the allergic symptoms during the month before (sneezing, stuffy nose, runny nose, nose-blowing, postnasal drip, epistaxis, and throat itch) was elicited by direct questioning and scored 0-3 as above. Any side effects experienced were recorded. The overall control of symptoms with the test spray was assessed at the end of each four-week trial period and rated as total, good, minor, none, or worse.
End-of-trial preferences-On completing the eight-week study the patient's and physician's preferences for one or neither of the treatments were recorded.
LABORATORY INVESTIGATIONS
At each visit to the clinic blood samples were taken for measurement of haemoglobin concentration and absolute and differential white cell counts. Nasal swabs were taken for fungal culture and to enable smears for eosinophil quantification to be made.
Results
One child withdrew during the placebo period because of nasal irritation. Table I gives the means of weekly symptom recorded in the diary cards. In most cases (14 out of 16 pairs of means) the symptoms were less during flunisolide treatment than during the corresponding period of placebo treatment. Table II lists the changes in symptom scores from baseline admission values as assessed by the physician.
On admission the two treatment groups had similar scores, and in general these were reduced by both flunisolide and placebo. Flunisolide, however, produced large reductions in scores more often than placebo. The improvement in scores was statistically significant for sneezing (in both treatment groups), stuffiness, postnasal drip, and Harrogate General Hospital, Harrogate HG2 7ND J K SARSFIELD, MD, MRCP, consultant paediatrician G E THOMSON, MB, BS, senior house officer throat itch. All these changes were recorded after treatment with flunisolide. Table III shows the patients' rating of overall control of symptoms after each treatment period. After flunisolide 21 of the 26 patients thought that they had derived benefit, whereas after placebo only six patients thought this. When each patient's responses to flunisolide and placebo were compared, flunisolide was found to provide a significantly higher degree of control of symptoms than placebo (P < 0-001; Wilcoxon signed rank test).
On completing the study 20 patients thought that the flunisolide period was more effective, four preferred the placebo period, and two rated the periods equally. Similarly, the physician's preference was for flunisolide in 20 cases, for placebo in three, and equal in the other three. These preferences favouring flunisolide were significant (P < 0 002). Eight side effects were reported by eight patients while using the active spray and 12 side effects by 10 patients while using placebo. These were irritation of the upper airways (15 cases), eye-watering (4), and abdoniinal discomfort (1). The upper respiratory tract irritation was usually mild and transient, though it resulted in one patient stopping treatment with placebo after two weeks.
Laboratory investigations showed no significant changes in haemo-BRITISH MEDICAL JOURNAL 14 jULY 1979 95 nmol/l (3 4 ,tg/100 ml). Inquiry showed that he had taken four 0-5-mg tablets of betamethasone (Betnesol) over the previous two days for an asthma attack. Repeat cortisol measurement 10 days later, and subsequent routine estimations while continuing with flunisolide, were all normal. The open subjective assessment showed no decline in symptom control. This satisfactory control was maintained in seven children who reduced the dose frequency to twice daily and five who reduced to a once-daily treatment. These reductions were usually made around mid-study. Ten children reported no side effects, four had transient nasal stinging, and two experienced mild, intermittent headache.
Discussion
This study showed the value of flunisolide in perennial rhinitis in children. Side effects were few and the spray was generally well tolerated. No interference with the pituitaryadrenal axis was detectable when using the therapeutic dose. The results concur with the reported efficacy and safety of flunisolide in perennial rhinitis in adults.5 Our study showed better control of symptoms with flunisolide, which may reflect the greater likelihood of an allergic aetiology in children. Other studies suggest that patients with a demonstrable allergic component to their disease respond better than those with non-allergic rhinitis,19 but this has been disputed.11
Nasal irritation was the commonest side effect. It was probably due to the vehicle solution acting on hypersensitive airways, as it occurred more often during the placebo period. This transient irritation may be offset by the anti-inflammatory effect of the steroid contained in the active spray. The choice of vehicle, however, enables metered doses to be delivered by a pump spray and avoids the need for halogenated hydrocarbon propellants.
The value of corticosteroids in allergic rhinitis is well established, and their systemic use may be justified for the shortterm treatment of hay fever. The dangers from long-term systemic treatment with corticosteroids forbids their use in We consider that this underlines the need for double-blind studies of drug effectiveness in children, in whom subjective responses may be as misleading as in adults.
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